What are the key takeaways from this Drug Story episode?

Key insights include: **Zolpidem gender dosing:** The FDA cut the recommended dose for women in half — from 10mg to 5mg — in 2013 after data showed zolpidem remained in women's bodies significantly longer than in men. Women accounted for two-thirds of zolpidem-related ER visits, which tripled between 2005 and 2010 as prescriptions rose post-patent expiration.; **Placebo effect benchmark:** When evaluating insomnia drugs, roughly 50% of placebo recipients report improved sleep without any active medication. Ambien's 10mg dose achieved ~90% positive response versus 51% for placebo — a meaningful but narrower gap than marketing implied. Understanding this helps patients critically evaluate any new sleep supplement or prescription claim.; **CBT-I over medication:** Cognitive Behavioral Therapy for Insomnia (CBT-I) is the current first-line recommended treatment by sleep medicine specialists because it addresses root behavioral causes rather than masking symptoms. Practical techniques include restricting time in bed to actual sleep duration and avoiding rewarding wakefulness with enjoyable activities like TV or snacking.

What did Andrew Crystal discuss on Drug Story?

Drug Story examines Ambien (zolpidem), the most prescribed sleeping pill in US history, through Caroline's firsthand account of sleepwalking, blackouts, and relationship damage, alongside psychiatrist Dr. Andrew Crystal's analysis of why insomnia treatment remains flawed and why Cognitive Behavioral Therapy outperforms medication for chronic sufferers. Key topics include: **Zolpidem gender dosing:** The FDA cut the recommended dose for women in half — from 10mg to 5mg — in 2013 after data showed zolpidem remained in women's bodies significantly longer than in men. Women accounted for two-thirds of zolpidem-related ER visits, which tripled between 2005 and 2010 as prescriptions rose post-patent expiration.; **Placebo effect benchmark:** When evaluating insomnia drugs, roughly 50% of placebo recipients report improved sleep without any active medication. Ambien's 10mg dose achieved ~90% positive response versus 51% for placebo — a meaningful but narrower gap than marketing implied. Understanding this helps patients critically evaluate any new sleep supplement or prescription claim..

How long is this episode of Drug Story?

This episode is 48 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Drug Story

On Ambien and insomnia

March 3, 2026

48 min episode · 2 min read

Andrew Crystal

Episode

48 min

Read time

2 min

Topics

Health & Wellness, Relationships, Fundraising & VC

AI-Generated Summary

Published Mar 4, 2026

Key Takeaways

✓Zolpidem gender dosing: The FDA cut the recommended dose for women in half — from 10mg to 5mg — in 2013 after data showed zolpidem remained in women's bodies significantly longer than in men. Women accounted for two-thirds of zolpidem-related ER visits, which tripled between 2005 and 2010 as prescriptions rose post-patent expiration.
✓Placebo effect benchmark: When evaluating insomnia drugs, roughly 50% of placebo recipients report improved sleep without any active medication. Ambien's 10mg dose achieved ~90% positive response versus 51% for placebo — a meaningful but narrower gap than marketing implied. Understanding this helps patients critically evaluate any new sleep supplement or prescription claim.
✓CBT-I over medication: Cognitive Behavioral Therapy for Insomnia (CBT-I) is the current first-line recommended treatment by sleep medicine specialists because it addresses root behavioral causes rather than masking symptoms. Practical techniques include restricting time in bed to actual sleep duration and avoiding rewarding wakefulness with enjoyable activities like TV or snacking.
✓Sleep hygiene specifics: Dr. Crystal identifies concrete behaviors that worsen insomnia: exercising too close to bedtime, excessive caffeine, and spending extra time in bed hoping to accumulate sleep. Counterintuitively, consolidating sleep into one shorter, consistent window — rather than extending bed time — produces measurably better daytime functioning and subjective rest quality.
✓Trazodone prescribing paradox: Trazodone, an antidepressant with no FDA approval for insomnia and no strong clinical evidence supporting its use as a sleep aid, is currently the most prescribed drug for insomnia in the US. Both the American Academy of Sleep Medicine and the American Association of Family Physicians actively recommend against prescribing it for this purpose.

What It Covers

Drug Story examines Ambien (zolpidem), the most prescribed sleeping pill in US history, through Caroline's firsthand account of sleepwalking, blackouts, and relationship damage, alongside psychiatrist Dr. Andrew Crystal's analysis of why insomnia treatment remains flawed and why Cognitive Behavioral Therapy outperforms medication for chronic sufferers.

Key Questions Answered

•Zolpidem gender dosing: The FDA cut the recommended dose for women in half — from 10mg to 5mg — in 2013 after data showed zolpidem remained in women's bodies significantly longer than in men. Women accounted for two-thirds of zolpidem-related ER visits, which tripled between 2005 and 2010 as prescriptions rose post-patent expiration.
•Placebo effect benchmark: When evaluating insomnia drugs, roughly 50% of placebo recipients report improved sleep without any active medication. Ambien's 10mg dose achieved ~90% positive response versus 51% for placebo — a meaningful but narrower gap than marketing implied. Understanding this helps patients critically evaluate any new sleep supplement or prescription claim.
•CBT-I over medication: Cognitive Behavioral Therapy for Insomnia (CBT-I) is the current first-line recommended treatment by sleep medicine specialists because it addresses root behavioral causes rather than masking symptoms. Practical techniques include restricting time in bed to actual sleep duration and avoiding rewarding wakefulness with enjoyable activities like TV or snacking.
•Sleep hygiene specifics: Dr. Crystal identifies concrete behaviors that worsen insomnia: exercising too close to bedtime, excessive caffeine, and spending extra time in bed hoping to accumulate sleep. Counterintuitively, consolidating sleep into one shorter, consistent window — rather than extending bed time — produces measurably better daytime functioning and subjective rest quality.
•Trazodone prescribing paradox: Trazodone, an antidepressant with no FDA approval for insomnia and no strong clinical evidence supporting its use as a sleep aid, is currently the most prescribed drug for insomnia in the US. Both the American Academy of Sleep Medicine and the American Association of Family Physicians actively recommend against prescribing it for this purpose.

Notable Moment

Caroline's neighbor physically stopped her from getting into her car while she was in an Ambien-induced blackout state — an event she has no memory of. She continued taking the drug despite losing two relationships and alarming her mother, describing the psychological toll as feeling like a fundamentally bad person.

Know someone who'd find this useful?